312 related articles for article (PubMed ID: 28621319)
1. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
Park JW; Lee JK; Witte ON; Huang J
Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
[TBL] [Abstract][Full Text] [Related]
2. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
4. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.
Xin Z; Zhang Y; Jiang Z; Zhao L; Fan L; Wang Y; Xie S; Shangguan X; Zhu Y; Pan J; Liu Q; Huang Y; Dong B; Xue W
Hum Pathol; 2018 Sep; 79():151-159. PubMed ID: 29885405
[TBL] [Abstract][Full Text] [Related]
5. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
6. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.
Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ
Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003
[TBL] [Abstract][Full Text] [Related]
7. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.
Han M; Li F; Zhang Y; Dai P; He J; Li Y; Zhu Y; Zheng J; Huang H; Bai F; Gao D
Cancer Cell; 2022 Nov; 40(11):1306-1323.e8. PubMed ID: 36332622
[TBL] [Abstract][Full Text] [Related]
8. PC3 is a cell line characteristic of prostatic small cell carcinoma.
Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
[TBL] [Abstract][Full Text] [Related]
10. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
11. The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Li W; Cohen A; Sun Y; Squires J; Braas D; Graeber TG; Du L; Li G; Li Z; Xu X; Chen X; Huang J
Mol Cancer Res; 2016 Apr; 14(4):344-53. PubMed ID: 26832214
[TBL] [Abstract][Full Text] [Related]
12. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
[TBL] [Abstract][Full Text] [Related]
14. Models of neuroendocrine prostate cancer.
Berman-Booty LD; Knudsen KE
Endocr Relat Cancer; 2015 Feb; 22(1):R33-49. PubMed ID: 25349195
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
[TBL] [Abstract][Full Text] [Related]
18. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141
[TBL] [Abstract][Full Text] [Related]
19. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
20. Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model?
Lopez-Barcons LA
Asian J Androl; 2010 May; 12(3):308-14. PubMed ID: 20023690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]